CANNABIS STRAINS
Everything you need to know about indica-classified cannabis: what the science actually says, why terpenes drive the body high, 20-plus strain reference table, and growing advantages over sativa varieties.
The term Cannabis indica was first formalised by the French naturalist Jean-Baptiste Lamarck in 1785, who described cannabis plants collected from India as distinct from European hemp in leaf shape, intoxicating properties, and use in producing hashish. The Linnaean species Cannabis sativa had been named in 1753; indica was designated as a second species, and the two-species framework entered cannabis taxonomy.
In practical cannabis retail and horticulture, indica refers to a cluster of physical traits that trace back to cannabis landraces from Afghanistan, Pakistan, the Hindu Kush mountain range, and the surrounding regions: broad, dark-green fan leaves, compact bushy growth structure, dense resinous buds, relatively short stature (60–150 cm indoors), and a shorter photoperiod-triggered flowering window of 7 to 9 weeks. These traits made indica-descended genetics particularly valuable for indoor cultivation — short plants finish faster and fit more easily into controlled environments.
| Characteristic | Indica | Sativa | Practical Implication |
|---|---|---|---|
| Leaf shape | Broad, wide, short blades | Narrow, long, finger-like | Visual identification in veg; indica easier to identify |
| Plant height | 60–150 cm indoors | 150–300+ cm indoors | Indicas suited for low-ceiling grows |
| Flowering time | 7–9 weeks | 10–14 weeks | Indicas allow more harvests per year |
| Bud structure | Dense, compact, heavy | Loose, airy, elongated | Dense buds hold moisture; humidity management critical |
| Yield per m² | Higher (shorter, more per sq ft) | Variable (tall, fewer per sq ft) | Indicas more space-efficient in grow rooms |
| Typical terpenes | Myrcene, linalool, caryophyllene | Terpinolene, limonene, ocimene | Terpenes drive effect differences more than plant type |
| Climate origin | Hindu Kush, Afghanistan, Pakistan | Equatorial (Southeast Asia, LatAm) | Indicas handle cool temps and humidity changes better |
In 2015, Sawler et al. published a genome-wide study of 81 cannabis samples in PLOS ONE, analysing genetic relationships between hemp, marijuana, indica, and sativa varieties. The study found that indica and sativa labels correlate with geographical origin — Afghan/Central Asian landraces on one branch, equatorial landraces on another — but that the genetic clustering does not reliably predict the intoxicating effects experienced by consumers. In other words, the indica-body-high and sativa-head-high dichotomy is not hardwired into the genome in the way the industry label implies.
This does not mean the labels are useless. The correlation between indica-classified strains and high-myrcene, high-linalool terpene profiles is consistent enough to have practical predictive value. What the Sawler research debunked is the idea that “indica” is a distinct species with biologically encoded sedative properties. The effects come from the chemical profile — primarily terpenes — not from the plant’s leaf shape or geographic ancestry. The indica label persists because breeders selecting for the Afghan/Hindu Kush terpene signature consistently produce strains with sedating profiles, making the label a useful shorthand even if it is taxonomically imprecise.
The characteristic indica experience — full-body relaxation, muscle release, appetite stimulation, and progressive sedation — is produced by the interaction of THC with the endocannabinoid system, amplified and shaped by the sedating terpene profile dominant in indica-classified strains.
| Terpene | Aroma | Effect Contribution | Mechanism | Example Indica Strains |
|---|---|---|---|---|
| Myrcene | Earthy, musky, tropical | Sedation, muscle relaxation, couch-lock | GABA-A potentiation; increased BBB permeability for THC | OG Kush, Granddaddy Purple, Bubba Kush |
| Linalool | Floral, lavender, sweet | Anxiety relief, calm, mood stabilisation | GABA-A positive modulation; glutamate inhibition | Northern Lights, Master Kush, Do-Si-Dos |
| Caryophyllene | Spicy, peppery, clove | Anti-inflammatory, stress relief | CB2 agonist; NF-κB pathway modulation | OG Kush, Skywalker OG, Zkittlez |
| Terpinolene (trace) | Piney, floral, herbaceous | Mild uplift (trace amounts in indicas) | Dopamine modulation; antioxidant | Some OG phenotypes; blueberry crosses |
The following table covers 20-plus widely available indica and indica-dominant hybrid strains. Data reflects typical laboratory-tested samples; individual batches may vary by phenotype, growing conditions, and cure quality.
| Strain | THC | CBD | Dominant Terpene | Primary Use | Flower Time |
|---|---|---|---|---|---|
| Granddaddy Purple | 17–23% | <1% | Myrcene | Sleep, pain, appetite | 8–9 wks |
| Northern Lights | 16–21% | <1% | Myrcene | Sleep, stress, pain | 7–8 wks |
| Bubba Kush | 14–22% | <1% | Myrcene | Insomnia, muscle spasms | 8–9 wks |
| Purple Punch | 18–23% | <1% | Myrcene | Sleep, relaxation | 7–8 wks |
| Skywalker OG | 20–30% | <1% | Myrcene | Pain, insomnia, PTSD | 8–9 wks |
| Zkittlez | 15–23% | <1% | Caryophyllene | Relaxation, stress | 7–8 wks |
| Do-Si-Dos | 19–30% | <1% | Linalool | Anxiety, pain, sleep | 8–9 wks |
| Blue Kush | 14–20% | up to 1% | Myrcene | Stress, anxiety, mood | 8–9 wks |
| Master Kush | 16–20% | <1% | Myrcene | Sleep, pain, relaxation | 7–9 wks |
| Slurricane | 20–28% | <1% | Caryophyllene | Pain, insomnia, appetite | 8–9 wks |
| Ice Cream Cake | 20–25% | <1% | Linalool | Sleep, pain, anxiety | 8–9 wks |
| Forbidden Fruit | 23–26% | <1% | Myrcene | Relaxation, sleep | 8–9 wks |
| Grape Ape | 15–21% | <1% | Myrcene | Sleep, appetite, pain | 7–8 wks |
| Oreoz | 20–33% | <1% | Caryophyllene | Sleep, heavy body stone | 9–10 wks |
| Biscotti | 21–25% | <1% | Caryophyllene | Relaxation, creative, sleep | 8–9 wks |
| Blueberry | 15–20% | <1% | Myrcene | Relaxation, sleep, pain | 8–9 wks |
| Blue Cheese | 15–20% | <1% | Myrcene | Relaxation, pain, appetite | 8–9 wks |
| Afghani | 15–20% | up to 1% | Myrcene | Pain, insomnia, hash production | 7–8 wks |
| Hash Plant | 15–20% | up to 2% | Myrcene | Pain, muscle relaxation | 6–7 wks |
| Purple Haze | 17–22% | <1% | Terpinolene | Mood, creativity (sativa-leaning) | 9–10 wks |
Indica-dominant strains, particularly those with high myrcene and linalool expression, are among the most commonly used cannabis varieties in medical programmes. The body-focused effect profile aligns well with conditions requiring muscle relaxation, pain modulation, sleep induction, and anxiety management. Key evidence areas include:
The physical characteristics of indica-descended genetics translate directly into practical growing advantages that explain why indica and indica-dominant hybrids dominate indoor cannabis cultivation globally.
| Factor | Indica | Sativa | Advantage For |
|---|---|---|---|
| Flower time | 7–9 weeks | 10–14 weeks | Indica: 3–5 extra weeks of production per cycle |
| Plant height | 60–150 cm | 150–300 cm | Indica: low-ceiling tents and grow rooms |
| Yield per m² | 400–600 g/m² (typical) | 250–500 g/m² (typical) | Indica: higher grams per square foot of canopy |
| Harvest timing | Oct (Northern Hemisphere) | Nov–Dec or never finishes outdoors | Indica: avoids frost in temperate climates |
| Training response | ScrOG/topping works well | LST preferred; topping extends timeline significantly | Indica: more tolerant of aggressive training |
| Humidity tolerance | Dense buds require RH <55% late | Airy buds more mold-resistant | Sativa: less botrytis risk in dense colas |
For consumer decisions at a dispensary or seed bank, the most reliable predictor of effect is the terpene profile, not the indica-sativa label. A dispensary budtender or seed catalogue that provides terpene data allows far more accurate predictions than a simple indica-sativa designation. The practical framework: